Mechanisms of resistance imatinib (ST1571) in preclinical models and in leukemia patients

被引：44

作者：

Weisberg, E

Griffin, JD

机构：

[1] Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA

[2] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA

[3] Harvard Univ, Sch Med, Dept Med, Boston, MA USA

来源：

DRUG RESISTANCE UPDATES | 2001年 / 4卷 / 01期

关键词：

D O I：

10.1054/drup.2001.0180

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The tyrosine kinase inhibitor imatinib (ST 157I,Glivec) blocks the activity of the BCR/ABL oncogene and induces hematologic remissions in the majority of patients with chronic myeloid leukemia (CML). Glivec is an aminopyrimidine derivative that interacts with the ATP-binding site within the kinase domain of ABL and several other tyrosine kinases, including c-KIT, PDGF beta receptor, and ARG. The compound is currently in phase III clinical trials. Although patients with chronic phase CML have been found to develop drug resistance only rarely so far, patients in more advanced phases of the leukemia develop resistance frequently. The available information on Glivec resistance will be reviewed. (C) 2001 Harcourt Publishers Ltd.

引用

收藏

页码：22 / 28

页数：7

相关论文

共 51 条

[1] Erythropoietin and interleukin-3 activate tyrosine phosphorylation of CBL and association with CRK adaptor proteins [J].

Barber, DL ;

Mason, JM ;

Fukazawa, T ;

Reedquist, KA ;

Druker, BJ ;

Band, H ;

DAndrea, AD .

BLOOD, 1997, 89 (09) :3166-3174

[2] THE CHRONIC MYELOGENOUS LEUKEMIA SPECIFIC P210-PROTEIN IS THE PRODUCT OF THE BCR/ABL HYBRID GENE [J].

BEN-NERIAH, Y ;

DALEY, GQ ;

MESMASSON, AM ;

WITTE, ON ;

BALTIMORE, D .

SCIENCE, 1986, 233 (4760) :212-214

[3] Does BCR-ABL genomic rearrangement persist in CML patients in complete remission after interferon α therapy? [J].

Brizard, F ;

Chomel, JC ;

Veinstein, A ;

Rivet, J ;

Giraud, C ;

Kitzis, A ;

Guilhot, F ;

Brizard, A .

LEUKEMIA, 1998, 12 (07) :1076-1080

[4]

Buchdunger E, 1996, CANCER RES, V56, P100

[5]

Corbin AS, 2000, BLOOD, V96, p470A

[6] INDUCTION OF CHRONIC MYELOGENOUS LEUKEMIA IN MICE BY THE P210BCR/ABL GENE OF THE PHILADELPHIA-CHROMOSOME [J].

DALEY, GQ ;

VANETTEN, RA ;

BALTIMORE, D .

SCIENCE, 1990, 247 (4944) :824-830

[7] Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells [J].

Druker, BJ ;

Tamura, S ;

Buchdunger, E ;

Ohno, S ;

Segal, GM ;

Fanning, S ;

Zimmermann, J ;

Lydon, NB .

NATURE MEDICINE, 1996, 2 (05) :561-566

[8]

Druker BJ, 1999, BLOOD, V94, p368A

[9] Chronic myelogenous leukemia: Biology and therapy [J].

Faderl, S ;

Talpaz, M ;

Estrov, Z ;

Kantarjian, HM .

ANNALS OF INTERNAL MEDICINE, 1999, 131 (03) :207-219

[10] Role of α1 acid glycoprotein in the in vivo resistance of human BCR-ABL+ leukemic cells to the Abl inhibitor STI571 [J].

Gambacorti-Passerini, C ;

Barni, R ;

le Coutre, P ;

Zucchetti, M ;

Cabrita, G ;

Cleris, L ;

Rossi, F ;

Gianazza, E ;

Brueggen, J ;

Cozens, R ;

Pioltelli, P ;

Pogliani, E ;

Corneo, G ;

Formelli, F ;

D'Incalci, M .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (20) :1641-1650

← 1 2 3 4 5 6 →